Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer? [electronic resource]
Producer: 20160801Description: 387-394 p. digitalISSN:- 1433-7339
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant -- adverse effects
- Chemotherapy-Induced Febrile Neutropenia -- economics
- Cost-Benefit Analysis
- Cyclophosphamide -- administration & dosage
- Decision Support Techniques
- Docetaxel
- Female
- Granulocyte Colony-Stimulating Factor -- economics
- Humans
- Middle Aged
- Primary Prevention
- Quality-Adjusted Life Years
- Risk Factors
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.